SI-BONE, Inc. (NASDAQ:SIBN) Receives Consensus Rating of “Buy” from Brokerages

SI-BONE, Inc. (NASDAQ:SIBN) has earned a consensus rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $23.00.

A number of brokerages have recently issued reports on SIBN. Truist Financial boosted their target price on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of SI-BONE in a report on Monday.

SI-BONE Stock Up 2.7 %

Shares of NASDAQ SIBN opened at $16.92 on Friday. The firm has a fifty day moving average of $13.76 and a 200-day moving average of $14.28. SI-BONE has a 52-week low of $11.70 and a 52-week high of $21.64. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $709.59 million, a PE ratio of -18.39 and a beta of 1.16.

Insider Activity

In related news, CFO Anshul Maheshwari sold 5,304 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the sale, the chief financial officer now directly owns 189,319 shares of the company’s stock, valued at $2,633,427.29. This represents a 2.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Anthony J. Recupero sold 3,937 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.60, for a total transaction of $49,606.20. Following the transaction, the insider now directly owns 228,554 shares of the company’s stock, valued at approximately $2,879,780.40. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 27,348 shares of company stock worth $356,349. 3.90% of the stock is currently owned by insiders.

Institutional Trading of SI-BONE

Hedge funds and other institutional investors have recently bought and sold shares of the company. Harbor Capital Advisors Inc. grew its position in shares of SI-BONE by 35.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company’s stock worth $11,791,000 after acquiring an additional 220,555 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in SI-BONE by 14.7% during the third quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company’s stock worth $2,486,000 after purchasing an additional 22,732 shares during the last quarter. Franklin Resources Inc. boosted its holdings in SI-BONE by 9.4% in the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock worth $265,000 after purchasing an additional 1,745 shares during the period. Barclays PLC increased its stake in SI-BONE by 190.8% during the third quarter. Barclays PLC now owns 96,623 shares of the company’s stock valued at $1,350,000 after purchasing an additional 63,402 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in SI-BONE by 3.4% during the third quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock valued at $12,921,000 after purchasing an additional 30,005 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.